NasdaqGS:RVMDBiotechs
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next
Revolution Medicines, Inc. has reported its second-quarter 2026 results, with net loss rising to US$644.37 million (US$3.06 basic and diluted loss per share), and US$1.10 billion in net loss for the first half of 2026, while advancing daraxonrasib through FDA review on paradigm-changing Phase 3 data in metastatic pancreatic cancer.
An important development is that more than 2,000 patients have already received daraxonrasib through compassionate use, highlighting real-world demand even before...